Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays

Leukemia Research

Volumn 38, Issue 6, 2014, Pages 682-690

  Pauly, Frida ^a   Smedby, Karin E ^b   Jerkeman, Mats ^c   Hjalgrim, Henrik ^d   Ohlsson, Mattias ^a,e   Rosenquist, Richard ^f   Borrebaeck, Carl A K ^a   Wingren, Christer ^a  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d STATENS SERUM INSTITUT   (Denmark)

^e LUND UNIVERSITY   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

Author keywords

B cell lymphoma; Biomarker; CLL; Disease heterogeneity; DLBCL; FL; MCL; Plasma protein profiling

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; APOLIPOPROTEIN A1; BETA GALACTOSIDASE; BIOLOGICAL MARKER; BRUTON TYROSINE KINASE; CD40 ANTIGEN; CD40 LIGAND; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S; CYSTATIN; EOTAXIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; PLASMA PROTEIN; RECOMBINANT ANTIBODY;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; PROTEIN TARGETING;

B-CELL LYMPHOMA; BIOMARKER; CLL; DISEASE HETEROGENEITY; DLBCL; FL; MCL; PLASMA PROTEIN PROFILING;

AGED; ANTIBODIES; BLOOD PROTEINS; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PILOT PROJECTS; PROTEIN ARRAY ANALYSIS; PROTEOME; RECOMBINANT PROTEINS;

EID: 84900431021     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.03.010     Document Type: Article

References (41)

1. Thaunat O., Morelon E., Defrance T. AmBvalent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood 2010, 116:515-521.
2. Shankland K.R., Armitage J.O., Hancock B.W. Non-Hodgkin lymphoma. Lancet 2012, 380:848-857.
3. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
4. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
5. Fais F., Ghiotto F., Hashimoto S., Sellars B., Valetto A., Allen S.L., et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998, 102:1515-1525.
6. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia: presented in part at the 40th Annual Meeting of The American Society of Hematology, held in Miami Beach, FL, December 4-8, 1998. Blood 1999, 94:1840-1847.
7. Elenitoba-Johnson K.S.J., Gascoyne R.D., Lim M.S., Chhanabai M., Jaffe E.S., Raffeld M. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998, 91:4677-4685.
8. Prognostic markers in diffuse large B-cell lymphoma. Leuk Lymphoma 2010, 51:1588-1589.
9. Freedman A. Follicular lymphoma: 2012 update on diagnosis and management. Am J Hematol 2012, 87:988-995.
10. Vose J.M. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2012, 87:604-609.
11. Tilly H., Vitolo U., Walewski J., da Silva M.G., Shpilberg O., André M., et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23:vii78-vii82.
12. Dighiero G., Hamblin T.J. Chronic lymphocytic leukaemia. Lancet 2008, 371:1017-1029.
13. Idikio H.A. Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains. Int J Clin Exp Pathol 2009, 3:169-176.
14. Borrebaeck C.A.K., Wingren C. Design of high-density antibody microarrays for disease proteomics: key technological issues. J Proteomics 2009, 72:928-935.
15. Wingren C., Sandstrom A., Segersvard R., Carlsson A., Andersson R., Lohr M., et al. Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res 2012, 72:2481-2490.
16. Melbye M., Smedby K.E., Lehtinen T., Rostgaard K., Glimelius B., Munksgaard L., et al. Atopy and risk of non-Hodgkin lymphoma. J Natl Cancer Inst 2007, 99:158-166.
17. Carlsson A., Persson O., Ingvarsson J., Widegren B., Salford L., Borrebaeck C.A.K., et al. Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients. Proteomics Clin Appl 2010, 4:591-602.
18. Soderlind E., Strandberg L., Jirholt P., Kobayashi N., Alexeiva V., Aberg A.-M., et al. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol 2000, 18:852-856.
19. Ewert S., Huber T., Honegger A., Pluckthun A. Biophysical properties of human antibody variable domains. J Mol Biol 2003, 325:531-553.
20. Borrebaeck C.K., Wingren C. Protein microarrays 2011, 247-262. Humana Press. U. Korf (Ed.).
21. Ingvarsson J., Larsson A., Sjöholm A.G., Truedsson L., Jansson B., Borrebaeck C.A.K., et al. Design of recombinant antibody microarrays for serum protein profiling: targeting of complement proteins. J Proteome Res 2007, 6:3527-3536.
22. Kristensson M., Olsson K., Carlson J., Wullt B., Sturfelt G., Borrebaeck C.A.K., et al. Design of recombinant antibody microarrays for urinary proteomics. Proteomics Clin Appl 2012, 6:291-296.
23. Wingren C., Ingvarsson J., Dexlin L., Szul D., Borrebaeck C.A.K. Design of recombinant antibody microarrays for complex proteome analysis: choice of sample labeling-tag and solid support. Proteomics 2007, 7:3055-3065.
24. Persson J., Bäckström M., Johansson H., Jirström K., Hansson G.C., Ohlin M. Molecular evolution of specific human antibody against MUC1 mucin results in improved recognition of the antigen on tumor cells. Tumor Biol 2009, 30:221-231.
25. Gustavsson E., Ek S., Steen J., Kristensson M., Älgenäs C., Uhlén M., et al. Surrogate antigens as targets for proteome-wide binder selection. New Biotechnol 2011, 28:302-311.
26. Carlsson A., Wuttge D.M., Ingvarsson J., Bengtsson A.A., Sturfelt G., Borrebaeck C.A.K., et al. Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays. Mol Cell Proteomics 2011, 10.
27. Dexlin-Mellby L., Sandström A., Centlow M., Nygren S., Hansson S.R., Borrebaeck C.A.K., et al. Tissue proteome profiling of preeclamptic placenta using recombinant antibody microarrays. Proteomics Clin Appl 2010, 4:794-807.
28. Ingvarsson J., Wingren C., Carlsson A., Ellmark P., Wahren B., Engström G., et al. Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics 2008, 8:2211-2219.
29. Pauly F., Dexlin-Mellby L., Ek S., Ohlin M., Olsson N., Jirstrom K., et al. Protein expression profiling of formalin-fixed paraffin-embedded tissue using recombinant antibody microarrays. J Proteome Res 2013, 12:5943-5953.
30. Carlsson A., Wingren C., Ingvarsson J., Ellmark P., Baldertorp B., Fernö M., et al. Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur J Cancer 2008, 44:472-480.
31. Ihaka R., Gentleman R.R. A language for data analysis and graphics. J Comput Graph Stat 1996, 5:299-314.
32. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868.
33. Davies D.L., Bouldin D.W. A cluster separation measure. IEEE Trans Pattern Anal Machine Intell 1979, PAMI-1:224-227.
34. Carlsson A., Wingren C., Kristensson M., Rose C., Fernö M., Olsson H., et al. Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc Natl Acad Sci USA 2011, 108:14252-14257.
35. Ghobrial I.M., McCormick D.J., Kaufmann S.H., Leontovich A.A., Loegering D.A., Dai N.T., et al. Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood 2005, 105:3722-3730.
36. Lossos I.S., Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:995-1007.
37. Perry A.M., Mitrovic Z., Chan W.C. Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control 2012, 19:214-226.
38. Rutkowski M.J., Sughrue M.E., Kane A.J., Mills S.A., Parsa A.T. Cancer and the complement cascade. Mol Cancer Res 2010, 8:1453-1465.
39. Toney L.M., Cattoretti G., Graf J.A., Merghoub T., Pandolfi P.-P., Dalla-Favera R., et al. BCL-6 regulates chemokine gene transcription in macrophages. Nat Immunol 2000, 214-220.
40. Edlefsen K.L., Martínez-Maza O., Madeleine M.M., Magpantay L., Mirick D.K., Kopecky K.J., et al. Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype. Int J Cancer 2014.
41. Wallstrom G., Anderson K.S., LaBaer J. Biomarker discovery for heterogeneous diseases. Cancer Epidemiol Biomarkers Prev 2013, 22:747-755.